Mendelsohn – using history as a guide – suggests there will be a layering of new laws, with, for example, a push for changes ...

Researchers from the National Institutes of Health (NIH) are applying artificial intelligence to the recruitment of ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

"Astellas stands by the clinical profile of Izervay, the only FDA-approved GA treatment that consistently demonstrated ...

Grifols is anticipating a period of strong growth on the back of its recently FDA-approved intravenous immunoglobulin product ...

As Global Head of Oncology for IQVIA Biotech, Gerhard du Toit manages all aspects of oncology clinical trials, optimising ...

In our final video from ESMO 2024, web editor Nicole Raleigh spoke with Dr Meredith McKean, a melanoma investigator at the Sarah Cannon Research Institute. The conversation explores the five-year ...

In unusual circumstances, Ipsen has been given the green light for its odevixibat drug for severe itching (pruritus) in patients with rare liver disease Alagille syndrome (ALGS) in the EU – for ...

Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive Giovanni Caforio as ...

Tackling the fibroblast cells that form scar tissue around tumours takes down a barrier that prevents or inhibits the effect of many therapies. There’s an increasing focus on using drugs to ...

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC) in the US for almost a decade. With the FDA approval of Gilead's ...